Here's why Abbott Labs stock is getting dinged after a strong earnings beat

Here's why Abbott Labs stock is getting dinged after a strong earnings beat
Advertisement

Advertisement
Advertisement

Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada.

Ethan Miller | Getty Images

Abbott Labs delivered a second-quarter earnings beat on Thursday, but the company’s ongoing litigation over its baby formula โ€” plus softer guidance for the current quarter โ€” is dragging down shares. We view the pullback as an opportunity.